[go: up one dir, main page]

AR059074A1 - 4-fenilpiperidinas sustituidas y una composicion farmaceutica - Google Patents

4-fenilpiperidinas sustituidas y una composicion farmaceutica

Info

Publication number
AR059074A1
AR059074A1 ARP070100224A ARP070100224A AR059074A1 AR 059074 A1 AR059074 A1 AR 059074A1 AR P070100224 A ARP070100224 A AR P070100224A AR P070100224 A ARP070100224 A AR P070100224A AR 059074 A1 AR059074 A1 AR 059074A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
alk
hydroxy
aminocarbonyl
Prior art date
Application number
ARP070100224A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of AR059074A1 publication Critical patent/AR059074A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La solicitud se refiere a 4-fenilpiperidinas sustituidas y una composicion farmacéutica en base al compuesto. Estos compuestos son utiles como medicinas, en especial como inhibidores de renina. usanse en enfermedades cardiovasculares (hipertension), insuficiencia cardíaca y renal. Reivindicacion 1: Un compuesto de la formula general (1) donde (A) R1 es heterociclilo sustituido con oxo u oxido o como se indica en (B) o (C), en particular azepanilo, benzo[1,3]dioxolilo, benzofuranilo, benzoimidazolilo, 4H-benzo[1,4]oxazinilo, benzooxazolilo, 4H-benzo[1,4ltiazinilo, quinolinilo, 2H-cromenilo, dihidro-benzo[e][1,4]diazepinilo, dihidrobenzofuranilo, 3,4- dihidro-2H-benzo[1,4joxazinilo, dihidro-3H-benzo[1,4joxazinilo, dihidrobenzo[d][1,3]oxazinilo, 3,4-dihidro-2H-benzo[1,4]tiazinilo, dihidro-2H-1gamma6-benzo[1,4]tiazinilo, dihidro-1H-quinazolinilo, 1a,7b-dihidro-1Hciclopropa[c]cromenilo, dihidroimidazolilo, 1,3-dihidroindolilo, 2,3-dihidroindolilo, dihidro-1H- pirido[2,3-b][1,4]oxazinilo, indazolilo, indolilo, 3H-isobenzofuranilo, [1,5]naftiridilo, oxazolilo, ftalazinilo, piperidinilo, pirazolilo, 1H-pirido[2,3-b][1,4]oxazinilo, piridilo, 1H-pirrolizinilo, 1H-pirrolo[2,3-b]piridilo, pirrolilo, tetrahidrobenzo[e][1,4}diazepinilo, 3H-tieno[2,3-d]pirimidinilo, tetrahidro-quinoxalinilo, 1,1a,2,7b-tetrahidrociclopropa[c]cromenilo, tetrahidropiranilo o triazinilo; o (B) R1 es arilo que está sustituido con 1-4-acetamidinil-alquilo C1-8, acil- alcoxi C1-8- alquilo C1-8, (N-acil)-alcoxi C1-8-alquil C1-8-amino, alcoxi C1-8, alcoxi C1-8-alcoxi C1-8, alcoxi C1-8-alcoxi C1-8-alquilo C1-8, alcoxi C18-alquilo C1-8, (N-alcoxi C1-8)-alquil C1-8-aminocarbonil-alcoxi C1-8, (N-alcoxi C1-8)- alquil C1- 8-aminocarbonil-alquilo C1-8, alcoxi C1-8-alquil C1-8-carbamoilo, alcoxi C1-8-alquil C1-8carbonilo, alcoxi C1-8-alquil C1-8-carbonilamino, 1-alcoxi C1-8-alquil C1-8-imidazol-2-ilo, 2-alcoxi C1-8-alquil C1-8-4-oxoimidazol-1-ilo, 1-alcoxi C1- 8-alquil C1-8-tetrazol-5-ilo, 5-alcoxi C1-8-alquil C1-8-tetrazol-1-ilo, 6-alcoxi-aminocarbonil-alcoxi C1-8, alcoxi C1-8-aminocarbonil-alquilo C1-8, alcoxi C1-8-carbonilo, alcoxi C1-8-carbonil-alcoxi C1-8, alcoxi C1-8-carbonil-alquilo C1-8, alcoxi C1- 8- carbonilamino-alcoxi C1-8, alcoxi C1-.8-carbonilamino-alquilo C1-8, alquilo C1-8, (N-alquil C1-8)-alcoxi C1-8-alquil C1-8-carbamoílo, (N-alquil C1-8)-alcoxi C1-8-alquil C1-8-carbonilamino, (N-alquil C1-8)-alcoxi C1-8-carbonilamino, (N-alquil C1-8)- alquil C=-8-carbonilamino-alcoxi C1-8, (N-alquil C1-8)-alquil C0-8-carbonilamino-alquilo C1-8, (N-alquil C1-8)-alquil C1-8-sulfonilamino-alcoxi C1-8, (N-alquil C1-8)-alquil C1-8-sulfonilamino-alquilo C1-8, alquil C1-8-amidinilo, alquil C18- aminocarbonil-aIcoxi C1-8, di-alquil C1-8-aminocarbonil-alcoxi C1-8, alquil C1-8-aminocarbonil-alcoxi C1-8-alquilo C1-8, alquil C1-8-aminocarbonil-alquilo C1-8, alquil C1-8-aminocarbonilamino-alcoxi C1-8, alquil C1-8-aminocarbonilamino-alquilo C1-8, di-alquil C1-8-aminocarbonil-alquilo C1-8, alquil C1-8-amino-alcoxi C2-8, di-alquil C1-8-amino-alcoxi C2-8, alquil C1-8-amino-alquilo C1-8, di-alquil C1-8-amino-alquilo C1-8, alquil C1-8-carbamoíIo, di-alquil C1-8-carbamoílo, alquil C0-8- carbonilamino-alcoxi C1-8, alquil C0-8-carbonilamino, alquil C0-8-carbonilamino-alquilo C1-8, alquil C1-8-carboniloxi-alcoxi C1-8, alquil C1-8-carboniloxi-alquilo C1-8, alquil C1-8-sulfonilo, alquil C1-8-sulfonil-alcoxi C1-8, alquil C1-8-sulfonil- alquilo C1-8, alquil C1-8-sulfonilamino-alcoxi C1-8, alquil C1-8-sulfonilamino-alquilo C1-8, carbamoílo, carbamoil-alcoxi C1-8, carbamoil-alquilo C1-8, carboxi-alcoxi C1-8, carboxi-alcoxi C1-8-alquilo C1-8, carboxi-alquilo C1-8, ciano, ciano-alcoxi C1-8, ciano-alquilo C1-8, cicloalquil C3-8-alcoxi C1-8, cicloalquil C3-8-alquilo C1-8, cicloalquil C3-8-carbonilamino-alcoxi C1-8, cicloalquil C3-8-carbonilamino-alquilo C1-8, O,N-dimetilhidroxilamino-alquilo C1-8, halogeno, hidroxi-alcoxi C1-8- alcoxi C1-8, hidroxi-alcoxi C1-8-alquilo C1-8, hidroxi-alquilo C1-8, (N-hidroxi)-alquil C1-8-aminocarbonil-alcoxi C1-8, (N-hidroxi)-alquil C1-8-aminocarbonil-alquiloC1-8, (N-hidroxi)aminocarbonil-alcoxiC1-8, (N-hidroxi)aminocarbonil-alquiloC1-8, 2- oxooxazolidinil-alcoxi C1-8, 2- oxooxazolidinil-alquilo C1-8, O-metiloximil-alquiloC1-8, polihalo-alcoxi C1-8 o polihalo-alquilo C1-8, o (C) R1 es arilo que está sustituido con 3-acetamidometilpirrolidinilo, 3-alcoxi C1-8-alquil C1-8- pirrolidinilo, 3,4-dihidroxipirrolidinilo, 2,6-dimetilmorfolinilo, 3,5-dimetilmorfolinilo, dioxanilo, dioxolanilo, 4,4-dioxotiomorfolinilo, ditianilo, ditiolanilo, 2-hidroximetilpirrolidinilo, 4-hidroxipiperidinilo, 3-hidroxipirrolidinilo, imidazolil-alcoxi, imidazolilalquilo, 2-metilimidazolilalcoxi, 2-metilimidazolilalquilo, 3-metil-[1,2,4]-oxadiazol-5-ilalcoxi, 5-metil-[1,2,4]-oxadiazol-3-ilalcoxi, 3-metil-[1,2,4]-oxadiazol-5-ilalquilo, 5-metil-[1,2,4]-oxadiazol-3-ilalquilo, 4- metilpiperazinilo, 5- metiltetrazol-1-ilalcoxi, 5-metiltetrazol-1-ilalquilo, morfolinilo, [1,2,4]-oxadiazol-5-ilalcoxi, [1,2,4]- oxadiazol-5-ilalquilo, oxazol-4-ilalcoxi, oxazol-4-ilalquilo, 2-oxo-[1,3]oxazinilo, 2-oxooxazolidinilo, 2- oxoimidazolidinilo, 2- oxopirrolidinilo, 4-oxo-piperidinilo, 2-oxopirrolidinilalcoxi, 2-oxopirrolidinilalquilo, 2-oxotetrahidropirimidinilo, 4-oxotiomorfolinilo, piperazinilo, piperidinilo, pirrolidinilo, pirrolilo, [1,2,4]-triazo-1-il-alcoxi, [1,2,4]-triazol-4- ilalcoxi, [1,2,4]-triazol-1-ilalquilo, [1,2,4]-triazol-4-ilalquilo, tetrazol-1-ilalcoxi, tetrazol-2-ilalcoxi, tetrazol-5-ilalcoxi, tetrazol-1 -ilalquilo, tetrazol-2-ilalquilo, tetrazol-5-ilalquilo, tiazol-4-ilalcoxi, tiazol-4- ilalquilo o tiomorfolinilo; o (D) R1 es arilo cuando X es -O-CHR6-CO-NR4-R1 u -O-CHR6-CO-NR4-Z, donde Z es Alk-R1 donde Alk es alquilenoC1-8; o (E) R1 es arilo cuando X es -O-Z, donde Z es Alk-NR4-R1 o X es -Z, donde Z es - Alk-NR4-R1, dondeAlkesalquilenoC1-8; R2 a) está ausente cuando W es ciano; o b) es alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-8-alquilo C1-8, alcoxi C1-8- cicloalquil C3-8-alquilo C1-8, alquil C1-8-sulfanil-alquilo C1-8, alquil C1-8-sulfonil- alquilo C1-8 cuando W es -O- o -S-; R3 a) es alcoxi C1-8 sustituido con halogeno y/o hidroxi, alcoxi C1-8-alcoxi C1-8 sustituido con halogeno y/o hidroxi, alcoxi C1-8-alcoxi C1-8 ramificado, amino-alcoxi C1-8 N-mono- o N,N-di-alquilado C1-8, alcoxi C1-8-alquil C1-8-amino-alcoxi C1-8 opcionalmente N-alquilado C1-8, amino-alquil C0-8-carbonil-alcoxi C1-8 opcionalmente N-mono- o N,N-di-alquilado C1-8, hidroxi-alquil C0-8-carbonil-alcoxi C0-8, alcoxi C1-8-alquil C0-8-carbonil-alcoxi C0-8, alquil C1-8-carbonilamino-alcoxi C1-8, ciano-alcoxi C1-8, cicloalquil C3-8-alcoxi C0-8 sustituido, heterociclil-alcoxi C0-8, heterociclil-alquil C0-8-amino-alquilC0-8-carbonil-alcoxiC0-8 opcionalmente N-alquilado C1-8, alquil C18-sulfonil-alcoxi C1- 8, alquinil C2-8-oxi, heterociclil- alquinil C2-8-oxi, amino-alquinil C2-8-oxi opcionalmente N-mono- o N,N-di-alquilado C1-8, aminocarbonil-alquinil C2-8-oxi N-mono- o N,N-di-alquilado C1-8, heterociclilcarbonil-alcoxi C0-8, amino-alquilo C1-8 opcionalmente N-mono- o N,N-di-alquilado C1-8, alcoxi C1-8-alquil C1-8-amino-alquilo C1-8 opcionalmente N-alquilado C1-8, amino-alquil C0-8-carbonil-alquilo C0-8 opcionalmente N-mono- o N,N-di-alquilado C1-8 y opcionalmente sustituido con hidroxi, heterociclil-alquil C0-8amino-alquil C0-8- carbonil-alquilo C0-8 opcionalmente N-alquilado C1-8, alcoxi C1-8-alquilo C1-8 opcionalmente sustituido con halogeno o hidroxi, hidroxi-alquilo C1-8 opcionalmente sustituido con halogeno o hidroxi, hidroxi- alquil C1-8-amino-alquilo C1-8 opcionalmente N-alquilado C1-8, heterociclilcarbonil-alquilo C0-8, heterociclilcarbonil-alquil C0-8-amino-alquilo C1-8, heterociclil-alquilo C1-8, alcoxi C1-8-carbonilamino-alquilo C1-8, heterociclil-alquil C0-8- carbonilamino-alquilo C1-8 opcionalmente sustituido con halogeno, cicloalquil C3-8-alquil C0-8-carbonilamino-alquilo C1-8 opcionalmente sustituido con halogeno o alquil C1-8-carbonilamino- alquilo C1-8 opcionalmente sustituido con halogeno; o adicionalmente b) es hidroxi, alcoxi no sustituido, alcoxi C1-8-alcoxi C1-8 no ramificado no sustituido o cicloalquil C3-8-alcoxi C0-8 no sustituido si -W-R2 no es alcoxi C1-8; R4 es acilo, alcoxi C1-8-alquilo C1-8, alquilo C1-8, aril-alquilo C1-8, cicloalquil C3-8- alquilo C0-8 o hidrogeno; R5 es alcoxi C1-8-carbonil-alquilo C1-8, alquilo C1-8, carboxi-alquilo C1-8 o H; R6 es acilo, alquenilo C2-8, alquilo C1-8, aril-alquilo C1-8 o hidrogeno; X es Z, -O-Z o -S-Z, donde el enlace que se origina a partir de un átomo de oxigeno o de azufre conduce a un átomo de C saturado del grupo Z, o es un grupo -CHR6-Z, -CHOR4-Z, -O-CO-Z, -O-CO-R1, -CO-Z, -C=NOR5-Z, -O-CHR6-Z, -O-CHR6-CO-NR4-Z, -O-CHR6-CO-NR4-R1 u -O-CHR6-R1; W es -O-, - S- o ciano; Z es Alk-C1-8-R1, alquenilen C2-8-R1, Alk-R1 sustituido con hidroxi, -O-R1, -S-R1, -O-Alk-R1, -S-Alk-R1, -Alk-O-R1, -Alk-S-R1 o -Alk-NR4-R1, donde Alk es alquileno C1-8; y donde (a) X es -CH-R6-Z si Z es -O-R1 o -S-R1; (b) X es - CH-R6-Z si Z es -O-Alk-R1 o -S-Alk-R1; y (c) Z es alquenilen C2-8-R1, -Alk-O-R1, -Alk-S-R1 o -Alk-NR4-R1 si X es Z; y una de sus sales, con preferencia una de sus sales farmacéuticamente aceptables.
ARP070100224A 2006-01-19 2007-01-18 4-fenilpiperidinas sustituidas y una composicion farmaceutica AR059074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH872006 2006-01-19

Publications (1)

Publication Number Publication Date
AR059074A1 true AR059074A1 (es) 2008-03-12

Family

ID=37943937

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100224A AR059074A1 (es) 2006-01-19 2007-01-18 4-fenilpiperidinas sustituidas y una composicion farmaceutica

Country Status (10)

Country Link
US (1) US20090029981A1 (es)
EP (1) EP1973903A1 (es)
JP (1) JP2009523762A (es)
CN (1) CN101370806A (es)
AR (1) AR059074A1 (es)
BR (1) BRPI0706631A2 (es)
CA (1) CA2637459A1 (es)
IL (1) IL192799A0 (es)
TW (1) TW200804359A (es)
WO (1) WO2007082907A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
EP2018862A1 (en) * 2007-07-25 2009-01-28 Speedel Experimenta AG Substituted piperidines as therapeutic compounds
CN101918398A (zh) * 2007-11-02 2010-12-15 诺瓦提斯公司 作为肾素抑制剂的4,4-二取代的哌啶类
TW200932241A (en) * 2007-12-05 2009-08-01 Speedel Experimenta Ag Organic compounds
RU2010129690A (ru) 2007-12-19 2012-01-27 Дайниппон Сумитомо Фарма Ко., Лтд. (Jp) Бициклические гетероциклические производные
JP4800445B2 (ja) 2008-06-19 2011-10-26 武田薬品工業株式会社 複素環化合物およびその用途
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
JP5331883B2 (ja) 2009-06-24 2013-10-30 大日本住友製薬株式会社 Ｎ−置換−環状アミノ誘導体
HRP20171415T4 (hr) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
US9659260B2 (en) 2011-03-15 2017-05-23 Dan Caligor Calendar based task and time management systems and methods
US9324060B2 (en) * 2011-05-10 2016-04-26 International Business Machines Corporation Displaying a plurality of calendar entries
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN116041169A (zh) * 2022-07-29 2023-05-02 北京先通国际医药科技股份有限公司 一种合成修饰脂肪酸型pet试剂前体关键中间体的工艺路线及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE242213T1 (de) * 1995-09-07 2003-06-15 Hoffmann La Roche Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
US6197959B1 (en) * 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
TW200513461A (en) * 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
TW200613274A (en) * 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
CA2601108A1 (en) 2005-03-31 2006-10-05 Speedel Experimenta Ag 3,4,5-substituted piperidines as renin inhibitors
TW200722424A (en) * 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines

Also Published As

Publication number Publication date
JP2009523762A (ja) 2009-06-25
IL192799A0 (en) 2009-02-11
BRPI0706631A2 (pt) 2011-04-05
CN101370806A (zh) 2009-02-18
US20090029981A1 (en) 2009-01-29
CA2637459A1 (en) 2007-07-26
EP1973903A1 (en) 2008-10-01
WO2007082907A1 (en) 2007-07-26
TW200804359A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
AR059074A1 (es) 4-fenilpiperidinas sustituidas y una composicion farmaceutica
AR053836A1 (es) Piperdinas 3,4,5-sustituidas
AR053348A1 (es) Piperidinas sustituidas con actividad inhibitoria de la enzima renina, composiciones farmaceuticas que las contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades cardiovasculares y la insuficiencia renal.
AR053406A1 (es) Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
AR066999A2 (es) Piperidinas sustituidas, preparados farmaceuticos y uso como inhibidores de renina
AR056197A1 (es) Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial
PE20060486A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
PE20080827A1 (es) N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2
AR061651A1 (es) Analogos de piridina ii
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20070586A1 (es) Compuestos de (4-piperidinil)-1,3-dihidro-2h-bencimidazol-2-ona sustituidos como agonistas del receptor muscarinico m1
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
MX2009014002A (es) Derivados imidazol como antagonistas del receptor ccr-2.
AR060651A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales
AR069480A1 (es) Derivados de 2-amino-pirimidina
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20081454A1 (es) Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
AR060605A1 (es) Derivados de diazepano como antagonistas del receptor ccr2
PE20120056A1 (es) Derivados de indol como antagonistas del receptor crth2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal